DaVita Inc.
NYSE:DVAMedical - Care Facilities
+$1.60 today
- Market cap
- $10.18B
- Beta
- 0.91
- P/E (TTM)
- 18.2
- EPS (TTM)
- $11.60
Volume 1.12M
Average 0.84M
DVA Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
DaVita Inc.NYSE: DVA
Gross Profit · Q2 FY2026 · quarter ended Jun 2026
Gross profit growth accelerates
Q2 FY2026 gross profit of $1.16B rose 3.9% year over year, ahead of the +1.5% change in trailing-twelve-month gross profit. Sequentially, it rose 8.3% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.
Context
- Gross profit amounted to 27.0% of revenue in FY2025, down 5.9 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +3.9% holds above the trailing-twelve-month pace of +1.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 3.68B USD
- Year-over-year change
- -12.6%
- 4-year CAGR
- +0.3%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.68B | -12.6% |
| FY2024 | 2024-12-31 | 4.22B | +10.4% |
| FY2023 | 2023-12-31 | 3.82B | +12.4% |
| FY2022 | 2022-12-31 | 3.4B | -6.7% |
| FY2021 | 2021-12-31 | 3.65B | — |
Gross Profit vs competitors
How DVA compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.5% is the 2nd highest of 3, against a peer median of -2.0%.
- Gross profit amounts to 31.0% of revenue for DVA, versus a peer median of 28.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €5.12B EUR | +6.3% | +0.9% | 26.4% | |
| LTM Jun 2026 | $4.35B USD | +1.5% | +2.7% | 31.0% | |
| LTM Jun 2026 | $3.45B USD | -10.2% | -1.6% | 30.1% | |
| Peer median (excluding DVA) | — | -2.0% | -0.4% | 28.2% | |
Competitors are the stored peer set for DVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.62B | 11.61B | 12.14B | 12.82B | 13.64B |
| Cost of Revenue | 7.97B | 8.21B | 8.32B | 8.6B | 9.96B |
| Gross Profit | 3.65B | 3.4B | 3.82B | 4.22B | 3.68B |
| Gross Margin | 31.4% | 29.3% | 31.5% | 32.9% | 27.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.2B | 1.36B | 1.47B | 1.54B | 1.67B |
| Operating Expenses | 1.85B | 2.06B | 2.22B | 2.13B | 1.67B |
| Depreciation & Amortization | 680.62M | 732.6M | 745.44M | 723.86M | 715.35M |
| EBITDA | 2.48B | 2.06B | 2.32B | 2.72B | 2.64B |
| EBITDA Margin | 21.4% | 17.7% | 19.1% | 21.3% | 19.4% |
| Operating Income | 1.8B | 1.34B | 1.6B | 2.09B | 2.01B |
| Operating Margin | 15.5% | 11.5% | 13.2% | 16.3% | 14.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 285.25M | 357.02M | 398.55M | 470.47M | 549.67M |
| Other Income / Expenses | (278.88M) | (372.78M) | (425.69M) | (560.09M) | (663.79M) |
| Income Before Tax | 1.52B | 966.28M | 1.18B | 1.53B | 1.35B |
| Pre-Tax Margin | 13.1% | 8.3% | 9.7% | 11.9% | 9.9% |
| Income Tax Expense | 306.73M | 198.09M | 220.12M | 279.66M | 293.11M |
| Net Income | 978.45M | 560.4M | 691.54M | 936.34M | 746.8M |
| Net Margin | 8.4% | 4.8% | 5.7% | 7.3% | 5.5% |
| EPS (Basic) | 9.30 | 5.88 | 7.62 | 11.02 | 9.72 |
| EPS (Diluted) | 8.90 | 5.71 | 7.42 | 10.73 | 9.51 |
| Weighted Avg Shares | 105.23M | 92.99M | 90.79M | 84.99M | 86.1M |
| Weighted Avg Shares (Diluted) | 109.95M | 95.83M | 93.18M | 87.27M | 88.1M |
DaVita Inc.
NYSE:DVA
Intrinsic Alpha fair value
Locked
Current Price
$161.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.